Company Filing History:
Years Active: 2008-2009
Title: Innovations of Matthew Hoffmann
Introduction
Matthew Hoffmann is an accomplished inventor based in Pottstown, PA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target central nervous system disorders. With a total of 2 patents to his name, Hoffmann's work has garnered attention in the scientific community.
Latest Patents
Hoffmann's latest patents include "Glucuronide metabolites and epimers thereof of tigecycline" and "Dihydrobenzofuran derivatives and uses thereof." The first patent identifies a glucuronide metabolite of tigecycline and its corresponding epimer, which have been found in humans treated with the drug. Mass spectral data were utilized to elucidate these structures. The second patent describes compounds that act as agonists or partial agonists of the 2C subtype of brain serotonin receptors. These compounds are useful for treating various central nervous system disorders, including schizophrenia.
Career Highlights
Matthew Hoffmann is currently employed at Wyeth, a prominent pharmaceutical company. His work at Wyeth has allowed him to focus on innovative research and development in the pharmaceutical sector. Hoffmann's contributions have been instrumental in advancing therapeutic options for patients.
Collaborations
Hoffmann has collaborated with notable colleagues, including Ronald A. Jordan and William DeMaio. These partnerships have fostered a collaborative environment that enhances the research and development process.
Conclusion
Matthew Hoffmann's innovative work in pharmaceuticals, particularly in the development of compounds for treating central nervous system disorders, showcases his dedication to advancing medical science. His contributions through patents and collaborations highlight the importance of innovation in improving healthcare outcomes.